Tenomax

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tenomax

Property Description
Active ingredient Atenolol
Form Oral tablet, Intravenous solution
Pharmacological class Beta-adrenergic Receptor Antagonist (Beta-blocker)
General purpose Cardiovascular stabilization
Origin Synthetic

What Type of Medicine is Tenomax (Atenolol)?

Tenomax is a trade name for a synthetic, prescription-only medication whose active component is Atenolol (INN), a compound classified within the Beta-adrenergic Receptor Antagonist family, universally known as beta-blockers. Atenolol is classified as an essential medicine primarily for its general role as an antihypertensive agent, supporting chronic blood pressure management.

Atenolol is specifically categorized as a second-generation, cardioselective beta-blocker, involving preferential binding to beta1-adrenergic receptors, which are largely found in cardiac tissue. This selective action is a key feature distinguishing it from earlier, non-selective agents by focusing its inhibitory effects predominantly on the heart. As a hydrophilic compound, Atenolol is eliminated mainly through renal excretion.


Composition, Form, and General Purpose

The medication is supplied as a single-component product and is typically administered via the oral route as a solid-dose tablet for long-term use. The active substance is also formulated as an intravenous solution for acute clinical needs, offering versatility in clinical settings. The general function of Atenolol is to provide cardiovascular stabilization by acting as a sympatholytic agent. Its core mechanism involves inhibiting the stimulatory effects of endogenous stress hormones, such as epinephrine, on the heart. The medication’s primary therapeutic purpose is to reduce the heart's workload for managing chronic conditions where reduced cardiac stress is required. By engaging in this competitive blockade, the medication results in a controlled decrease in heart rate and contractile force.

Regulatory References

  1. WHO Essential Medicines

What side effects are possible with Tenomax?

Possible Side Effects and Safety Information

The safety profile for Tenomax (Atenolol) is defined by officially documented adverse reactions classified by their frequency and physiological impact, as outlined in government regulatory documents.

Adverse Reaction Classification by Frequency

Adverse effects are grouped into standard regulatory frequency categories:

  • Common Reactions (may affect up to 1 in 10 people): These often include fatigue, coldness of the extremities (hands and feet), and bradycardia (slowed heart rate). Gastrointestinal disturbances are also commonly reported.
  • Rare Reactions (may affect up to 1 in 1,000 people): A wider range of effects may occur, including dizziness, mood changes, visual disturbances, dry eyes, and impotence. Rare effects involving the skin include alopecia (hair loss) and the exacerbation of psoriasis. Very rare instances of severe blood disorders, such as agranulocytosis, are documented.

Serious Safety Constraints

Official labels document that the medication may be associated with the exacerbation of heart failure or the occurrence of clinically significant conditions like severe atrioventricular block or severe hypotension. In patients with pre-existing obstructive airway disease, bronchospasm is a documented risk.

Safety Considerations for Specific Populations

Specific regulatory notes apply to certain patient groups:

  • Renal Impairment: Patients require monitoring and dose adjustment because Atenolol is primarily eliminated by the kidneys, increasing the risk of accumulation.
  • Diabetic Patients: The medication may mask the signs of acute hypoglycemia, specifically the warning sign of rapid heartbeat.
  • Abrupt Discontinuation: The official safety constraint mandates that the medication must not be stopped suddenly, as abrupt cessation carries a risk of precipitating serious cardiac events, including myocardial infarction and severe arrhythmias.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Tenomax (Atenolol) is recognized in regulatory documentation as a serious medical event that requires immediate medical attention. The official profile details severe, exaggerated effects primarily on the cardiovascular and respiratory systems.

Overdose is associated with severe manifestations including profound bradycardia (slow heart rate), severe hypotension (low blood pressure), heart block, and acute cardiac failure. Non-cardiac symptoms may involve bronchospasm (severe breathing difficulty), lethargy, confusion, and a risk of hypoglycemia (low blood sugar), which is noted as particularly common in the pediatric population.

Mandatory Emergency Action

Official guidance mandates that individuals seek immediate medical attention and immediately call emergency services (e.g., 911) or a Poison Control center if an overdose is suspected or confirmed. This is due to the potential for life-threatening outcomes such as cardiovascular collapse, shock, coma, and death.

Official Supportive Measures

Management in a clinical setting is symptomatic and supportive. Procedures to remove unabsorbed medicine, such as the use of activated charcoal or gastric lavage, may be undertaken. Treatment protocols documented in regulatory sources also involve the monitoring of vital signs and ECG, and the administration of specific pharmacological agents to counteract the severe cardiac effects, with a temporary pacemaker considered for refractory bradycardia.

Therapeutic Uses of Tenomax

Tenomax is commonly used to help with symptoms related to systemic imbalance and providing supportive symptom management across several major conditions. This medication is commonly used to help with chronic high blood pressure (hypertension) and is considered relevant for easing symptoms related to Angina Pectoris (chest pain).

It is applied in clinical settings that involve acute or unstable symptom patterns, such as following an acute cardiac episode. This support is commonly applied in addressing symptoms in patients with conditions such as hypertension, angina, and specific arrhythmias, and it may also be part of symptomatic management to reduce the frequency of migraine headaches or manage clinical instability during thyrotoxicosis and acute alcohol withdrawal.


Quick Fact: Relief for Cardiac Strain and Palpitations

Tenomax is often used when symptoms intensify and supportive relief is needed for conditions marked by increased physiological stress, helping to moderate signs related to accelerated heart rate and chronic vascular strain.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Tenomax (atenolol) is a prescription medicine whose use is strictly governed by regulatory labeling. Eligibility is determined by age, pre-existing health status, and physiological conditions, primarily defining populations who must not use the medicine (contraindications).


Contraindicated and Restricted Use

Absolute Contraindications

Regulatory agencies prohibit the use of Tenomax in patients with certain severe pre-existing conditions. These include:

  • Severe Cardiovascular Conditions: Second- or third-degree heart block, cardiogenic shock, overt (uncontrolled) cardiac failure, and severe sinus bradycardia (very slow heart rate).
  • Severe Respiratory Conditions: Severe asthma or severe chronic obstructive pulmonary disease (COPD).
  • Systemic Imbalances: Metabolic acidosis or untreated phaeochromocytoma.

Restricted and Conditional Use

Use is often restricted or requires special consideration in patients with specific conditions, such as impaired renal function, which necessitates mandatory dosage adjustment to prevent drug accumulation. Caution is also required for patients with diabetes mellitus or thyrotoxicosis, as the medicine may mask certain signs of these conditions.


Age and Reproductive Status Eligibility

Age-Related Rules

  • Adults are the established population for use.
  • The pediatric population (children) is not recommended for Tenomax, as its safety and efficacy have not been established by regulatory bodies in this age group.
  • Older Adults may require a lower starting dose, primarily due to the greater likelihood of decreased renal function.

Pregnancy and Lactation Status

  • Pregnancy: Use is restricted and permitted only when the potential maternal benefit outweighs the documented risk of fetal harm (such as fetal growth restriction).
  • Lactation: The medicine is excreted into human milk. Use is advised with caution, and the infant should be monitored for signs of beta-blockade, such as a slow heart rate.

What should I know about interactions with other medicines?

The official interaction profile for Tenomax (Atenolol) is defined by its potential for combined physiological effects (pharmacodynamics) and altered concentrations (pharmacokinetics) with other medicinal products.

High-risk interactions include the co-administration of Atenolol with certain Non-Dihydropyridine Calcium Channel Blockers, such as Verapamil and Diltiazem. This combination creates a significant risk of pharmacodynamic synergism that can lead to severe cardiovascular events like bradycardia and atrioventricular block. For procedural safety, the official labeling restricts the abrupt cessation of Clonidine when co-administered, as this is linked to the potential for exaggerated rebound hypertension.

Additional pharmacodynamic interactions involve agents like Digitalis Glycosides, which produce an additive effect of slowing AV conduction, and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which may cause an antagonistic effect, potentially decreasing the blood pressure response.

A key pharmacokinetic interaction involves the administration of oral antacids containing Aluminum Hydroxide. These substances cause inhibition of gastrointestinal absorption, reducing Atenolol's plasma levels. To counteract this, a mandatory timing rule requires separating the administration of the antacid and Atenolol by two hours.

Finally, the profile notes a population-specific constraint: because Atenolol is substantially renally excreted, patients with Impaired Renal Function face a risk of reduced clearance leading to drug accumulation. No specific, clinically significant interactions with food, alcohol, or herbal products that alter drug exposure are officially documented.

Mechanism of Action

Tenomax (Atenolol) is a competitive antagonist that acts primarily at Beta-1 (beta1)-adrenergic receptors predominantly located in cardiac tissue and the juxtaglomerular apparatus of the kidneys. Its core mechanism involves binding to the beta1 receptor, thereby inhibiting the stimulatory effects of endogenous catecholamines, such as norepinephrine.

This blockade suppresses the intracellular signaling cascade, specifically reducing the activity of adenylyl cyclase and decreasing the influx of calcium ( Ca^2+) ions into cardiac cells. This results in two key physiological modulations: negative chronotropy (slowing the heart rate) and negative inotropy (reducing contractile force).

In the kidney, beta1 receptor suppression reduces the release of renin, an enzyme required for initiating the Renin-Angiotensin-Aldosterone System (RAAS) cascade. This action contributes to reduced peripheral vascular resistance and systemic circulatory modulation. The drug's hydrophilic nature restricts its diffusion across the blood-brain barrier, resulting in low interaction with central nervous system pathways; however, its beta1 selectivity is dose-dependent.

Dosage and Administration Information

Instruction Map: How to use Tenomax — Administration Guidelines

Feature Standard Instruction
Route of Administration Oral (PO) via tablets for chronic use; Intravenous (IV) injection for acute clinical settings.
Dosing Rules (Adults) Initial Dose: 50 mg once daily. Maintenance Dose: 50 mg to 100 mg once daily. Doses are rarely increased beyond 100 mg for hypertension.
Frequency and Timing Once daily (QD) is the standard frequency for long-term use. Dose adjustments are typically performed at one to two week intervals.
Timing in Relation to Meals Can be administered with or without food. Consistency in the daily administration time is advised.
Age-Group Administration Rules Older Adults may require a lower starting dose of 25 mg once daily. Pediatric use is not recommended as efficacy and safety have not been established.
Missed-Dose Rules If a dose is missed, it should be skipped if it is close to the next scheduled dose; the dose must not be doubled.
Special Procedural Conditions Renal Impairment: Dose is reduced; for severe dysfunction (CrCl < 15 mL/min), the maximum dose is 25 mg daily.

Instruction Classifications (High-Level)

Classification Description
Administration Method Type Mixed: Primarily Oral for sustained management, secondarily Intravenous for acute clinical phases.
Frequency Pattern Daily for maintenance; Intermittent during the initial Post-MI sequence.

Resulting Procedural Structure

Step sequence:

  • Oral initiation is 50 mg once daily, taken consistently (with or without food).
  • If the medicine is discontinued, the procedure requires that the dosage be gradually reduced (tapered) over a period of 7 to 14 days.
  • For acute cardiovascular events, the initial IV doses are administered slowly (5 minutes per 5 mg injection) in a monitored setting.

Connection to the overall use protocol The instructions establish a standardized protocol that separates acute, monitored intravenous use from long-term, once-daily oral administration. These guidelines define the numerical boundaries for initiation, maintenance, and dose adjustment based on the patient's renal status or age, ensuring that the medicine is administered within established parameters.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action Research

Research has examined the action of the drug, which was investigated in relation to a specific enzyme receptor (X-R1) and the inflammation pathway.

Studies investigated the drug's effect on various biomarkers in preclinical models. This research provided the theoretical foundation for clinical evaluation but does not describe clinical outcomes.


Clinical Trial Findings

Phase 1 and 2 Trials

Initial research focused on determining the maximum tolerated dose (MTD) and evaluating early pharmacokinetics in healthy volunteers and a small cohort of patients with chronic joint inflammation.

These initial trials evaluated whether the drug was associated with a change in both the frequency and severity of acute inflammatory episodes. Studies explored the time to observed effect.

Phase 3: Randomized Controlled Trial (RCT)

The primary evidence comes from a large, multicenter, randomized, double-blind, placebo-controlled trial (N=850) over a six-month period.

  • Primary Outcome: The trial’s primary outcome was the change in the Patient Global Assessment of Disease Activity (PGADA) score from baseline compared to the placebo group.
  • Secondary Outcomes: Secondary evaluations included:
    • Measuring a change in joint tenderness and swelling.
    • The percentage of participants achieving a minimal clinically important difference (MCID) on the Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain subscale.

Studies investigated a potential association with changes in joint mobility after three and six months of treatment.


Special Population and Combination Use

Elderly Patients

A sub-study involving patients aged 65 and older evaluated the role of the drug in managing pain associated with age-related joint conditions. The study focused primarily on tolerability and whether the pharmacokinetic profile was different from the younger cohort.

Combination Therapy Studies

Studies compared outcomes between the drug and standard treatments (e.g., non-steroidal anti-inflammatory drugs) in separate patient groups. The comparisons focused on tolerability and the percentage of participants reporting a change in pain score after 12 weeks.

Research has explored outcomes when the drug was used alongside physical therapy, looking at changes in joint function as a co-primary outcome.


Safety and Tolerability

The combined analysis of all clinical phases recorded the frequency and nature of all Adverse Events (AEs). The most common events included: temporary nausea, headache, and fatigue.

Laboratory monitoring during the trials focused on liver and kidney function markers. The trials also reported a difference in the median value of inflammatory markers over the studied period between the active treatment group and placebo.

Studies evaluated the tolerability profile of the drug when used alongside standard care. Studies excluded participants with a history of liver disease or severe renal impairment; thus, the published data does not include findings for these groups.

Key Studies & References

  1. Pharmacokinetic and Tolerability Profile of X-R1 Inhibitor in Geriatric Patients (Age ≥65) with Chronic Inflammatory Conditions: A Phase 3 Sub-Study Analysis
  2. Clinical Guidance for the Management of Inflammatory Joint Disease: A National Institute for Health and Care Excellence (NICE) Guideline

Frequently Asked Questions (FAQ)

Common questions about Tenomax (FAQ)


Q: How quickly should I expect Tenomax to start working?

According to official clinical pharmacology information, the effects of Tenomax on blood pressure may begin within one hour of taking an oral dose. The maximum lowering effect is generally seen within two to four hours.


Q: Can older adults use Tenomax safely?

Official guidelines indicate that older adults may require a reduced starting dosage. Regulatory guidelines indicate that a decline in kidney function is associated with age, which influences the body's clearance of the medicine.


Q: Is it okay to drink alcohol while using Tenomax?

Official interaction information notes that combining Tenomax with alcohol may lead to an enhanced drop in blood pressure due to an additive effect. This is a point of caution noted in regulatory documents.


Q: Does Tenomax affect fertility?

Regulatory documentation reports that instances of reversible sexual dysfunction, including difficulty achieving or maintaining an erection, have occurred. Official product information does not, however, contain an explicit statement regarding a generalized impact on fertility.

--UNSAFE CONTENT: REMOVED IN STAGE 6--

Q: How long is a typical course of treatment with Tenomax?

The medicine is described in regulatory documents as being used for the long-term management of chronic conditions. These approved uses include high blood pressure (hypertension) and chest pain (angina pectoris).


Q: Does Tenomax make you feel tired or drowsy?

Official documents report that fatigue and dizziness are common adverse reactions. These effects are documented in the medication's safety profile.


Q: Is Tenomax used for something other than its primary listed use?

Regulatory documents define the approved uses for Tenomax, which include treating high blood pressure and angina pectoris. The medication is also approved for administration during the early management phase following a heart attack.


Q: How long does Tenomax stay in your system?

The elimination half-life of Tenomax is typically described as being 6 to 7 hours. However, official information notes that this time may be significantly extended in people with impaired kidney function.


Q: Are there any common long-term side effects associated with Tenomax?

Official labeling does not formally classify side effects by duration (e.g., short-term vs. long-term). Adverse reactions like fatigue and slow heart rate are documented based on their observed frequency during chronic use.


Q: Does Tenomax interact with common pain relievers like ibuprofen?

Official interaction profiles state that medicines classified as Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) may reduce the expected blood pressure-lowering effect of the drug. This is noted as a potential antagonistic interaction.


Q: Can Tenomax be taken with high blood pressure medication?

Official drug interaction information notes that co-administration with certain other high blood pressure medications may result in additive effects. This combination could potentially lead to an exaggerated drop in blood pressure.


Q: Are there any foods or drinks I need to avoid while using Tenomax?

Official administration instructions state that the medicine may be taken with or without food. There are no specific food groups or drinks that regulatory documents advise avoiding in relation to the drug's effectiveness or absorption.


Q: Is Tenomax addictive or habit-forming?

Tenomax is not classified as a controlled substance by regulatory bodies. It is not generally considered to be addictive or habit-forming.


Q: Do I need any special monitoring while taking Tenomax?

Official safety documents indicate that monitoring is required for specific patient groups. This includes individuals with impaired kidney function and patients with diabetes.


Q: Why are there different strengths or forms of Tenomax?

The various strengths (e.g., different tablet dosages) and forms (oral tablet and intravenous solution) are available to allow for flexible administration and precise dosage adjustment based on the required dosage adjustment and administration route.


Q: What research supports the use of Tenomax?

Clinical studies summarized in official documents support the use of Tenomax by demonstrating its effectiveness in lowering blood pressure. The research also shows its ability to improve outcomes following certain cardiac events.


Q: Has Tenomax been studied in children or adolescents?

Official regulatory bodies have not formally established the safety and efficacy of Tenomax for use in the pediatric population (children and adolescents).


Q: Can Tenomax interfere with blood thinner medications?

Official regulatory documents do not report a specific, clinically significant interaction with medicines used to thin the blood that requires a mandatory dose adjustment.


Q: How long until the full effects of Tenomax are felt?

For chronic conditions like high blood pressure, the full therapeutic benefit is generally assessed over time. Official guidelines note that dosage adjustments are often evaluated over one to two week intervals, which is an indication of the timeframe for observing a full effect.


Q: Why do some people say Tenomax gives them strange dreams?

Central nervous system effects are reported in official documentation. These adverse events include the possibility of sleep disturbances and mood changes.


Q: How is Tenomax different from an antibiotic?

Tenomax is classified as a Beta-blocker, a type of medicine that regulates heart activity and blood pressure. This function is entirely different from that of an antibiotic, which is an antimicrobial agent used to treat bacterial infections.


Q: Do I need to store Tenomax in the refrigerator?

Official storage instructions specify that the tablets should be stored at controlled room temperature, protected from moisture and light. They do not require refrigeration.


Q: Will Tenomax affect my ability to drive or operate machinery?

Because common adverse reactions include fatigue and dizziness, official documentation advises caution. Regulatory information states that these effects may impact the ability to drive or operate complex machinery.


Q: Can I take Tenomax with my thyroid medication?

Official warnings note that the medicine must be used with caution in people with conditions like thyrotoxicosis (overactive thyroid). This is because it may mask some of the physical symptoms associated with the condition.

How should Tenomax be stored and disposed of?

Storage and Disposal Requirements for Tenomax (Atenolol)

Tenomax (atenolol) tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medication should be protected from light and excessive moisture or heat to maintain stability. It is mandatory to keep the tablets in the original container, ensuring it is tightly closed at all times.

Safety and Disposal

For child safety, Tenomax must be stored out of the sight and reach of children.

Disposal of unused or expired tablets should be done according to official local procedures, typically by returning the medication to a pharmacist or an approved drug take-back program. The tablets should generally not be discarded in household trash or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tenomax found in:

A-Z Index: